Patient assistance and access programs for pembrolizumab — the MSD China initiatives bridging the access gap between NRDL-covered indications and out-of-pocket cost for non-covered indications — creates an important commercial market dimension, with the China Keytruda Market reflecting access programs as both humanitarian and commercial strategy enabling patient access while building market experience and oncologist engagement.

Buy-and-donate commercial model — the MSD China "购买赠药" (buy and donate) program where patients purchasing a specified initial course receive additional treatment free of charge reducing the effective per-cycle cost burden. This model enabling patients to access pembrolizumab for non-NRDL indications at reduced but still significant cost while MSD maintains the commercial relationship and revenue.

Compassionate use program access — the NMPA compassionate use framework enabling pre-approval access for life-threatening conditions through the Expanded Access Program. This regulatory pathway enabling MSD to provide pembrolizumab access in China before full NMPA approval for certain indications creating the early access commercial strategy.

Multi-level payer strategy — the combination of NHSA national coverage (for NRDL indications), provincial supplemental medical insurance (地方医保), commercial insurance (百万医疗险), and patient out-of-pocket collectively creating the multi-payer access framework. The provincial medical insurance programs in wealthy provinces (Guangdong, Zhejiang, Beijing) often supplementing national NRDL coverage for additional oncology indications at provincial budget.

Do you think MSD China's patient assistance programs are primarily humanitarian measures or primarily commercial strategies maintaining market engagement during the NRDL reimbursement gap period?

FAQ

What patient access programs exist for Keytruda in China? Keytruda China patient access mechanisms: NRDL coverage: included indications covered by national medical insurance; approximately seventy percent price reduction; prescription at any NRDL formulary hospital; provincial coverage: select provinces supplementing NRDL for additional indications; Guangdong, Zhejiang, Shanghai more comprehensive; buy-and-donate programs: MSD China specific programs; patients purchasing specified cycles; receiving additional free treatment; effective cost reduction; compassionate use: NMPA expanded access; pre-approval access for life-threatening conditions; limited applications; commercial insurance: 百万医疗险 covering pembrolizumab for non-NRDL indications; commercial insurance coverage growing; patient assistance: MSD China social service team; patient navigation support; documentation assistance; combined: complex multi-channel access with significant gaps for non-NRDL, non-insured patients.

How do Chinese provincial medical insurance programs supplement NRDL? Provincial medical insurance supplementation: national NRDL: covered at standard rate nationally; provincial expansion: individual provinces adding additional drugs beyond national NRDL; Guangdong 省医保: more comprehensive oncology coverage; Zhejiang: progressive supplemental coverage; Shanghai: municipal medical insurance additional benefits; methods: provincial pharmaceutical catalog additions; special case review programs; high-cost drug negotiation at provincial level; commercial impact: MSD monitoring provincial coverage for indications not yet NRDL included; commercial team engaging provincial health commission; patient documentation: patients documenting provincial coverage in addition to national; geographic inequality: wealthy coastal provinces better coverage than interior provinces; policy direction: NHSA encouraging provincial harmonization long-term; commercial implication: provincial access providing partial revenue generation awaiting national NRDL inclusion.

#ChinaKeytruda #PatientAccessChina #KeytrudaAccess #PembrolizumabAccess #ChinaCancerAccess #MSDaccessProgram